Julie C. Smith

Combined Targeted Therapies for First‐line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab‐Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

H. Linden, B. Kurland, J. Gralow, 2019, Clinical breast cancer.

Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium

J. Pagel, T. Gooley, S. Petersdorf, 2010, Leukemia & lymphoma.

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.

E. Estey, M. Sorror, B. Sandmaier, 2021, Blood.

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients.

E. Estey, M. Sorror, B. Sandmaier, 2022, Blood.

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

E. Estey, M. Sorror, B. Sandmaier, 2018, Blood.